Date Filed | Type | Description |
10/02/2023 |
8-K
| Quarterly results |
09/28/2023 |
8-K
| Quarterly results |
08/23/2023 |
4
| Moran Kyle (CFO) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Sold 37,062 shares
@ $4.752, valued at
$176.1k
|
|
08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/09/2023 |
4
| Tan Aik Na (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| TAKANASHI KEN (10% Owner) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| Wagner Heidi L (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| CORRIGAN MARK (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| Rawcliffe Adrian (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| Verdine Gregory L. (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/09/2023 |
4
| HENRY CHRISTIAN O (Director) has filed a Form 4 on Wave Life Sciences Ltd.
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
08/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/03/2023 |
8-K
| Investor presentation, Quarterly results |
05/23/2023 |
8-K
| Investor presentation |
05/05/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/03/2023 |
8-K
| Investor presentation, Quarterly results |
04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/22/2023 |
8-K
| Quarterly results |
03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
02/14/2023 |
SC 13G/A
| BB BIOTECH AG reports a 5.2% stake in WAVE LIFE SCIENCES LTD. |
02/14/2023 |
SC 13G/A
| 683 Capital Management, LLC reports a 6.9% stake in Wave Life Sciences Ltd. |
02/14/2023 |
SC 13G/A
| MAVERICK CAPITAL LTD reports a 8.2% stake in Wave Life Sciences Ltd. |
02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/30/2023 |
SC 13G
| GSK PLC reports a 11% stake in Wave Life Sciences Ltd. |
01/30/2023 |
3
| GSK PLC (10% Owner) has filed a Form 3 on Wave Life Sciences Ltd. |
01/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events Interactive Data |
01/09/2023 |
8-K
| Investor presentation |
12/22/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
12/19/2022 |
8-K/A
| Quarterly results |
12/19/2022 |
8-K
| Quarterly results |
|